
C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics Inc shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics Inc employs 146 staff and has a trailing 12-month revenue of around $31.1 million.
How to buy C4 Therapeutics Inc stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – CCCC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
C4 Therapeutics Inc stock price (NASDAQ: CCCC)
Use our graph to track the performance of CCCC stocks over time.C4 Therapeutics Inc shares at a glance
Latest market close | $3.14 |
---|---|
52-week range | $3.00 - $26.80 |
50-day moving average | $5.58 |
200-day moving average | $8.12 |
Wall St. target price | $22.42 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.52 |
Buy C4 Therapeutics Inc stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy C4 Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
C4 Therapeutics Inc price performance over time
Historical closes compared with the close of $3.14 from 2023-03-31
1 week (2023-03-24) | -11.30% |
---|---|
1 month (2023-03-01) | -37.76% |
3 months (2022-12-30) | -46.78% |
6 months (2022-09-30) | -64.20% |
1 year (2022-04-01) | -87.47% |
---|---|
2 years (2021-04-01) | -91.87% |
3 years (2020-03-28) | N/A |
5 years (2018-03-28) | N/A |
C4 Therapeutics Inc financials
Revenue TTM | $31.1 million |
---|---|
Gross profit TTM | $-86,745,000 |
Return on assets TTM | -17.27% |
Return on equity TTM | -37.76% |
Profit margin | 0% |
Book value | $5.91 |
Market capitalisation | $152.1 million |
TTM: trailing 12 months
C4 Therapeutics Inc share dividends
We're not expecting C4 Therapeutics Inc to pay a dividend over the next 12 months.
C4 Therapeutics Inc share price volatility
Over the last 12 months, C4 Therapeutics Inc's shares have ranged in value from as little as $2.995 up to $26.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while C4 Therapeutics Inc's is 2.2457. This would suggest that C4 Therapeutics Inc's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put C4 Therapeutics Inc's beta into context you can compare it against those of similar companies.
- Regeneron Pharmaceuticals (REGN.US): 0.2094
- Biogen (BIIB.US): 0.1926
- Alector (ALEC.US): 0.8336
C4 Therapeutics Inc overview
C4 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
C4 Therapeutics Inc in the news
Insiders who bought this year lost US$59k as C4 Therapeutics, Inc. (NASDAQ:CCCC) sheds US$27m in value
Frequently asked questions
What percentage of C4 Therapeutics Inc is owned by insiders or institutions?Currently 11.375% of C4 Therapeutics Inc shares are held by insiders and 81.047% by institutions. How many people work for C4 Therapeutics Inc?
Latest data suggests 146 work at C4 Therapeutics Inc. When does the fiscal year end for C4 Therapeutics Inc?
C4 Therapeutics Inc's fiscal year ends in December. Where is C4 Therapeutics Inc based?
C4 Therapeutics Inc's address is: 490 Arsenal Way, Watertown, MA, United States, 02472 What is C4 Therapeutics Inc's ISIN number?
C4 Therapeutics Inc's international securities identification number is: US12529R1077
More guides on Finder
-
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
Ask an Expert